GlassScriptPhysician profile
Kim W Smith
NPI 1811223464
$3,229.33
in general payments reported to CMS, 2019-2025
27 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $398 · 2022: $497 · 2023: $1,397 · 2024: $504 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.97 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,014.50 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $412.39 | 2021-2024 | Uzedy, Austedo |
| Abbvie INC. | $215.58 | 2021-2024 | |
| Corium, LLC | $195.95 | 2022-2024 | Azstarys |
| Alkermes, INC. | $193.02 | 2021-2023 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $175.12 | 2021-2025 | Fanapt, Hetlioz |
| Uswm, LLC | $155.59 | 2022-2023 | Lucemyra, Zimhi |
| Amgen INC. | $125.00 | 2025 | Repatha |
| Neurocrine Biosciences, INC. | $120.52 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.74 | 2021-2023 | |
| Noven Therapeutics, LLC | $83.54 | 2022-2023 | Secuado, Xelstrym |
| Otsuka America Pharmaceutical, INC. | $72.32 | 2022-2025 | Abilify Asimtufii, Abilify Maintena |
| Organogenesis INC. | $43.62 | 2025 | Apligraf |
| Convatec INC. | $33.77 | 2021 | |
| Abbott Laboratories | $30.62 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $29.92 | 2023 | Sublocade |
| Supernus Pharmaceuticals, INC. | $29.76 | 2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $26.80 | 2025 | Cobenfy |
| Spr Therapeutics, INC | $24.71 | 2024 | Sprint Pns System |
| Insulet Corporation | $21.76 | 2024 | Omnipod |
| Nevro Corp. | $21.41 | 2024 | Senza |
| Axsome Therapeutics, INC. | $18.04 | 2024 | Auvelity |
| Vertos Medical, INC. | $17.67 | 2022 | |
| Acadia Pharmaceuticals INC | $16.51 | 2025 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $14.90 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.29 | 2023 | Xifaxan, Trulance |
| Eisai INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.